X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Proceeds from the financing will enable Intrance to initiate pivotal U.S. clinical trials for the company’s lead product, Lecigon® (in the Nordic countries and European markets) for enteral infusion (light weight infusion pump) in advanced Parkinson’s disease patients.
Lead Product(s): Carbidopa,Etilevodopa,Entacapone
Therapeutic Area: Neurology Product Name: Lecigon
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Erik Selin
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 04, 2022
Details:
The novel gel formulation is of the three established Parkinson's active ingredients levodopa, carbidopa and entacapone has a positive effect on the bioavailability of levodopa in the body.
Lead Product(s): Etilevodopa,Carbidopa,Entacapone
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2021
Details:
By acquiring Lobsor Pharmaceuticals, STADA gains rights to a triple fixed combination (levodopa, carbidopa, entacapone), delivered via modern pump technology, that has already been successfully launched in Nordic countries.
Lead Product(s): Etilevodopa,Carbidopa,Entacapone
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: STADA Arzneimittel
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
